TGF-β1 is an autocrine mediator of renal tubular epithelial cell growth and collagen IV production

Experimental Biology and Medicine

Volumn 227, Issue 3, 2002, Pages 171-181

  Grande, Joseph P ^a,b   Warner, Gina M ^a   Walker, Henry J ^a   Yusufi, Ahad N K ^a   Cheng, Jingfei ^a   Gray, Catherine E ^a   Kopp, Jeffrey B ^c   Nath, Karl A ^a,b  

^a Department of Laboratory Medicine and Pathology ^*  (United States)

^b MAYO CLINIC   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Collagen IV; Kidney; Proliferation; TGF 1; Tubular epithelial cells

Indexed keywords

ANGIOTENSIN; COLLAGEN TYPE 4; GLUCOSE; MESSENGER RNA; PROTEIN P21; PROTEIN P27; THROMBOXANE A2; THYMIDINE; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CELL COUNT; CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SYNTHESIS; EXTRACELLULAR MATRIX; GENETIC TRANSCRIPTION; INJURY; KIDNEY TUBULE EPITHELIUM; KNOCKOUT MOUSE; MOUSE; NONHUMAN; NORTHERN BLOTTING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL DIVISION; CYTOLOGY; GENETICS; KIDNEY TUBULE; MOUSE MUTANT; PHYSIOLOGY; TRANSACTIVATION;

ANIMALIA;

ANIMALS; AUTOCRINE COMMUNICATION; CELL DIVISION; CELLS, CULTURED; COLLAGEN TYPE IV; KIDNEY TUBULES; MICE; MICE, KNOCKOUT; TRANS-ACTIVATION (GENETICS); TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0036517843     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020222700304     Document Type: Article

References (107)

1. Grande JP. Role of transforming growth factor-β in tissue injury and repair. Proc Soc Exp Biol Med 214:27-40, 1997.
2. Roberts A. Molecular and cell biology of TGF-β. Miner Electrolyte Metab 24:111-119, 1998.
3. Baird A, Durkin T. Inhibition of endothelial cell proliferation by type β-transforming growth factor: interactions with acidic and basic fibroblast growth factors. Biochem Biophys Res Commun 138(1):476-482, 1986.
4. Boyd FT, Massague J. Transforming growth factor-β inhibition of epithelial cell proliferation linked to the expression of a 53-kDa membrane receptor. J Biol Chem 264:2272-2278, 1989.
5. MacKay K, Striker LJ, Stauffer JW, Doi T, Agodoa LY, Striker GE. Transforming growth factor-β: murine glomerular receptors and responses of isolated glomerular cells. J Clin Invest 83:1160-1167, 1989.
6. Hu PP, Datto MB, Wang XF. Molecular mechanisms of transforming growth factor-β signaling. Endocr Rev 19(3):349-363, 1998.
7. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Genes Dev 13:804-816, 1999.
8. Grainger DJ, Metcalfe JC. A pivotal role for TGF-β in atherogenesis? Biol Rev Cambridge Philosophic Soc 70:571-596, 1995.
9. Bottinger E, Letterio J, Roberts A. Biology of TGF-β in knockout and transgenic mouse models. Kidney Int 51:1355-1360, 1997.
10. Border WA, Noble NA, Ketteler M. TGF-β: a cytokine mediator of glomerulosclerosis and a target for therapeutic intervention. Kidney Int 47:S59-S61, 1995.
11. Border WA, Ruoslahti E. Transforming growth factorβ in disease: the dark side of tissue repair. J Clin Invest 90:1-7, 1992.
12. Border WA, Noble NA. Transforming growth factor-β in tissue fibrosis. N Engl J Med 331:1286-1292, 1994.
13. Assoian RD, Fleurdelys BE, Stevenson HC, Miller PJ, Madtes DK, Raines EW, Ross R, Sporn MB. Expression and secretion of type β transforming growth factor by activated human macrophages. Proc Natl Acad Sci U S A 84:6020-6024, 1987.
14. Assoian RD, Sporn MB. Type β transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol 102:1219-1223, 1986.
15. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-β in human platelets. J Biol Chem 258:7155-7160, 1983.
16. Cavazzana AO, Miser JS, Jefferson J, Triche TJ. Experimental evidence for a neural origin of Ewing's sarcoma of bone. Am J Pathol 127:507-518, 1987.
17. Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. High glucose-induced transforming growth factor β1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest 101:160-169, 1998.
18. Hoffman BB, Sharma K, Ziyadeh FN. Potential role of TGF-β in diabetic nephropathy. Miner Electrolyte Metab 24:190-196, 1998.
19. Kirschenlohr KL, Metcalfe JC, Weissberg PL, Grainger DJ. Adult human aortic smooth muscle cells in culture produce active TGF-β. Am J Physiol 265:C571-C576, 1993.
20. Studer RK, Craven PA, DeRubertis FR. Antioxidant inhibition of protein kinase C-signaled increases in transforming growth factor-β in mesangial cells. Metabolism 46(8):918-925, 1997.
21. Border WA, Noble NA. Evidence that TGF-β should be a therapeutic target in diabetic nephropathy. Kidney Int 54(4):1390-1391, 1998.
22. Nath KA, Grande JP, Croatt A, Haugen J, Kim Y, Rosenberg ME. Redox regulation of renal DNA synthesis, TGF-β1 and collagen gene expression. Kidney Int 53:367-381, 1998.
23. Studer RK, Negrete H, Craven PA, DeRubertis FR. Protein kinase C signals thromboxane-induced increases in fibronectin synthesis and TGF-β bioactivity in mesangial cells. Kidney Int 48:422-430, 1995.
24. Lee H, Kim B, Hong H, Lim Y. LDL stimulates collagen mRNA synthesis in mesangial cells through induction of PK and TGF-β expression. Am J Physiol 277:F369-F376, 1999.
25. Nath K, Croatt A, Haggard J, Grande J. Renal response to repetitive exposure to heme proteins: chronic injury induced by an acute insult. Kidney Int 57:2423-2433, 2000.
26. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M, Roberts AB. Autoinduction of transforming growth factor-β 1 is mediated by the AP-1 complex. Mol Cell Biol 10: 1492-1497, 1990.
27. Diebold RJ, Eis MJ, Yin M, Ormsby I, Boivin GP, Darrow BJ, Saffitz JE, Doetschman T. Early-onset multifocal inflammation in the transforming growth factor-β 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci U S A 92(26):12215-12219, 1995.
28. Cook HT, Smith J, Salmon JA, Cattell V. Functional characteristics of macrophages in glomerulonephritis in the rat. Am J Pathol 134:431-437, 1989.
29. Kulkarni AB, Huh C-G, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. Transforming growth factor β-1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 90:770-774, 1993.
30. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice. Development 121:1845-1854, 1995.
31. Grande JP, Melder DC, Zinsmeister AR. Modulation of collagen gene expression by cytokines: stimulatory effect of transforming growth factor-β1, with divergent effects of epidermal growth factor and tumor necrosis factor-α on collagen type I and collagen type IV. J Lab Clin Med 130:476-486, 1997.
32. Grande J, Melder D, Zinsmeister A, Killen P. TGF-β1 induces collagen IV gene expression in NIH-3T3 cells. Lab Invest 69:387-395, 1993.
33. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132:6-13, 1983.
34. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci U S A 81:1991-1995, 1984.
35. Correa-Rotter R, Mariash CN, Rosenberg ME. Loading and transfer control for Northern hybridization. BioTechniques 12:154-158, 1992.
36. Coimbra T, Wiggins R, Noh JW, Merritt S, Phan SH. Transforming growth factor-β production in anti-glomerular basement membrane disease in the rabbit. Am J Pathol 138(1):223-234, 1991.
37. Danielpour D, Dart LL, Flanders KC, Roberts AB, Sporn MB. Immunodetection and quantitation of the two forms of transforming growth factor-β (TGF-β1 and TGF-β2) secreted by cells in culture. J Cell Physiol 138:79-86, 1989.
38. 4. Nature (London) 227:680-685, 1970.
39. Lowry O, Rosebrough A, Farr A, Randall R. Protein measurement with folin phenol reagent. J Biol Chem 193:265-275, 1951.
40. Grande JP, Melder DC, Kluge DL, Wieben ED. Structure of the rat collagen IV promoter. Biochim Biophys Acta 1309:85-88, 1996.
41. Miller EJ, Gay S. The collagens: an overview and update. Methods Enzymol 144:3-83, 1987.
42. Kuroki M, Takeshige K, Minakami S. ATP-induced calcium mobilization in human neutrophils. Biochem Biophys Acta 1012:103, 1989.
43. Kulkarni AB, Ward JM, Yaswen L, Mackall CL, Bauer SR, Huh CG, Gress RE, Karlsson S. Transforming growth factor-β1 null mice: an animal model for inflammatory disorders. Am J Pathol 146(1):264-275, 1995.
44. Boivin GP, O'Toole BA, Orsmby IE, Diebold RJ, Eis MJ, Doetschman T, Kier AB. Onset and progression of pathological lesions in transforming growth factor-β1-deficient mice. Am J Pathol 146(1):276-288, 1995.
45. Kulkarni AB, Karlsson S. Inflammation and TGF-β1: lessons from the TGF-β1 null mouse. Res Immunol 148(7):453-456, 1997.
46. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143-1155, 1984.
47. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20(1):1-17, 1992.
48. Jones ML, Warren JS. Monocyte chemoattractant protein 1 in a rat model of pulmonary granulomatosis. Lab Invest 66:498-503, 1992.
49. Fine LG, Ong ACM, Norman JT. Mechanisms of tubulo-interstitial injury in progressive renal diseases. Eur J Clin Invest 23(5):259-265, 1993.
50. Eddy AA. Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 5:1273-1287, 1994.
51. Niemir ZI, Stein H, Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R. PDGF and TGF-β contribute to the natural course of human IgA glomerulonephritis. Kidney Int 48:1530-1541, 1995.
52. Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-β in kidney disease. Am J Physiol 266:F829-F842, 1994.
53. Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen UL, Jerums G, Cooper ME. Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 47(3):414-422, 1998.
54. Taniguchi Y, Yorioka N, Masaki T, Asakimori Y, Yamashita K, Yamakido M. Localization of transforming growth factors β1 and β2 and epidermal growth factor in IgA nephropathy. Scand J Urol Nephrol 33(4):243-247, 1999.
55. Park IS, Kiyomoto H, Abboud SL, Abboud HE. Expression of transforming growth factor-β and type IV collagen in early streptozotocin-induced diabetes. Diabetes 46(3):473-480, 1997.
56. Won Hong S, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, Ziyadeh FN. Increased glomerular and tubular expression of transforming growth factor-β1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 158(5):1653-1663, 2001.
57. Wright EJ, McCaffrey TA, Robertson AP, Vaughan ED Jr, Felsen D. Chronic unilateral ureteral obstruction is associated with interstitial fibrosis and tubular expression of transforming growth factor-β. Lab Invest 74(2):528-537, 1996.
58. Jenkins JK, Huang H, Ndebele K, Salahudeen AK. Vitamin E inhibits renal mRNA expression of COX II, HO I, TGFβ, and osteopontin in the rat model of cyclosporine nephrotoxicity. Transplantation 71(2):331-334, 2001.
59. Suzuki K, Uetsuka K, Nakayama H, Doi K. Kinetics of transforming growth factor-β1 and extracellular matrix in renal tubulointerstitial lesions of mercuric chloride-treated Brown Norway rats. Int J Exp Pathol 80(3):125-132, 1999.
60. Gilbert RE, Wu LL, Kelly DJ, Cox A, Wilkinson-Berka JL, Johnston CI, Cooper ME. Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy: implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol 155(2):429-440, 1999.
61. Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN. Elevated glucose stimulates TGF-β gene expression and bioactivity in proximal tubule. Kidney Int 41:107-114, 1992.
62. Jones SC, Saunders HJ, Qi W, Pollock CA. Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells. Diabetologia 42(9):1113-1119, 1999.
63. Wolf G, Mueller E, Stahl RA, Ziyadeh FN. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β. J Clin Invest 92(3):1366-1372, 1993.
64. Wolf G, Zahner G, Schroeder R, Stahl RAK. Transforming growth factor-β mediates the angiotensin-II-induced stimulation of collagen type IV synthesis in cultured murine proximal tubular cells. Nephrol Dial Transplant 11:263-269, 1996.
65. Johnson DW, Saunders HJ, Johnson FJ, Huq SO, Field MJ, Pollock CA. Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells: roles of insulin-like growth factor I, transforming growth factor β1, and platelet-derived growth factor. J Pharmacol Exp Ther 289(1):535-542, 1999.
66. Pankewycz OG, Miao L, Isaacs R. Guan J, Pruett T, Haussmann G, Sturgill BC. Increased renal tubular expression of transforming growth factor-β in human allografts correlates with cyclosporine toxicity. Kidney Int 50(5):1634-1640, 1996.
67. Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engstrom U, Heldin C-H. Transforming growth factor-β1, -β2, and -β3 secreted by a human glioblastoma cell line: identification of small and different forms of large latent complexes. J Biol Chem 267:19482-19488, 1992.
68. Harpel JG, Metz CN, Kojima S, Rifkin DB. Control of transforming growth factor-β activity: latency vs. activation. Progress Growth Factor Res 4:321-335, 1992.
69. Pircher R, Jullien P, Lawrence DA. β-Transforming growth factor is stored in human blood platelets as a latent high molecular weight complex. Biochem Biophys Res Commun 136:30-37, 1986.
70. Lyons K, Graycar JL, Lee A, Hashmi S, Lindquist PB, Chen EY, Hogan BL, Derynck R. Vgr-1, a mammalian gene related to Xenopus Vg-1, is a member of the transforming growth factor-β gene superfamily. Proc Natl Acad Sci U S A 86:4554-4558, 1989.
71. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system. J Biol Chem 269:26775-26782, 1994.
72. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism. J Cell Biol 122:923-932, 1993.
73. Munger JS, Harpel JG, Gleizes P-E, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-β: structural features and mechanisms of activation. Kidney Int 51(5):1376-1382, 1997.
74. Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium. J Cell Biol 106:1659-1665, 1988.
75. Miyazono K, Heldin CH. Role for carbohydrate structures in TGF-β1 latency. Nature 338:158-160, 1989.
76. Donadio JV, Holub BJ, Bergstrahl EJ. Effects of n-3 fatty acids in IgA nephropathy. In: Kristensen SD, Schmidt EB, DeCaterina R, Endres S, Eds. n-3 Fatty Acids. Prevention and Treatment in Vascular Disease. Verona: Bi & Gi Publishers, p173-180, 1995.
77. Wilson HM, Minto AW, Brown PA, Erwig LP, Rees AJ. Transforming growth factor-β isoforms and glomerular injury in nephrotoxic nephritis. Kidney Int 57(6):2434-2444, 2000.
78. Shankland SJ, Pippin J, Pichler RH, Gordon KL, Friedman S, Gold LI, Johnson RJ, Couser WG. Differential expression of transforming growth factor-β isoforms and receptors in experimental membranous nephropathy. Kidney Int 50(1):116-124, 1996.
79. Tamaki K, Okuda S, Ando T, Iwamoto T, Nakayama M, Fujishima M. TGF-β1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy. Kidney Int 45:525-536, 1994.
80. Kang MJ, Ingram A, Ly H, Thai K, Scholey JW. Effects of diabetes and hypertension on glomerular transforming growth factor-β receptor expression. Kidney Int 58(4):1677-1685, 2000.
81. Sudarshan C, Yaswen L, Kulkarni A, Raghow R. Phenotypic consequences of transforming growth factor β-1 gene ablation in murine embryonic fibroblasts: autocrine control of cell proliferation and extracellular matrix biosynthesis. J Cell Physiol 176:67-75, 1998.
82. Grande J, Warner G, Walker H, Cheng J, Gray C, Yusufi A. TGF-β1 promotes collagen IV production in vascular smooth muscle cells through activation of the ERK and P38 pathways, but not the JNK pathway. J Am Soc Nephrol 11:528A, 2000.
83. Hayashida T, Poncelet A-C, Hubchak S, HW S. TGF-β1 activates MAP kinase in human mesangial cells: a possible role in collagen expression. Kidney Int 56:1710-1720, 1999.
84. Isono M, Iglesias-de La Cruz M, Chen S, Hong S, Ziyadeh F. Extracellular signal-regulated kinase mediates stimulation of TGF-β1 and matrix by high glucose in mesangial cells. J Am Soc Nephrol 11:2222-2230, 2000.
85. Hu PP, Shen X, Huang D, Liu Y, Counter C, Wang XF. The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor-β. J Biol Chem 274(50):35381-35387, 1999.
86. Schoecklmann HO, Rupprecht HD, Zauner I, Sterzel RB. TGF-β1-induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-cdk 2 activation and retinoblastoma protein phosphorylation. Kidney Int 51:1228-1236, 1997.
87. Robson CN, Gnanapragasam V, Byrne RL, Collins AT, Neal DE. Transforming growth factor-β1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. J Endocrinol 160(2):257-266, 1999.
88. Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science 260(5107):536-539, 1993.
89. Shankland SJ. Cell-cycle control and renal disease. Kidney Int 52:294-308, 1997.
90. Rao R. Targets for cancer therapy in the cell cycle pathway. Curr Opin Oncol 8:516-524, 1996.
91. Polyak K, Kato J-Y, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8:9-22, 1994.
92. Kip1. Kidney Int 51:1088-1099, 1997.
93. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K-I. Mice lacking p27kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720, 1996.
94. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang X-F. Transforming growth factor-β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A 92:5545-5549, 1995.
95. Miyazaki M, Ohashi R, Tsuji T, Mihara K, Gohda E, Namba M. Transforming growth factor-β1 stimulates or inhibits cell growth via down- or up-regulation of p21/Waf1. Biochem Biophys Res Commun 246:873-880, 1998.
96. Datto MB, Yu Y, Wang XF. Functional analysis of the transforming growth factor-β responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem 270(48):28623-28628, 1995.
97. Shankland SJ, Scholey JW, Ly H, Thai K. Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int 46:430-442, 1994.
98. WAF1, CIP1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy. J Am Soc Nephrol 9(6):986-993, 1998.
99. WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int 56(5):1691-1699, 1999.
100. WAF1/CIP1 gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci U S A 96:10830-10835, 1999.
101. Hara M, Mase D, Inaba S, Higuchi A, Tanizawa T, Yamanaka N, Sugisaki Y, Sado Y, Okada T. Immunohistochemical localization of glomerular basement membrane antigens in various renal diseases. Virchows Arch Pathol Anat 408:403-419, 1986.
102. Striker LM, Killen PD, Chi E, Striker GE. The composition of glomerulosclerosis. I. Studies in focal sclerosis, crescentic glomerulonephritis, and membranoproliferative glomerulonephritis. Lab Invest 51(2):181-192, 1984.
103. Fukatsu A, Matsuo S, Killen PD, Martin GR, Andres GA, Brentjens JR. The glomerular distribution of type IV collagen and laminin in human membranous glomerulonephritis. Hum Pathol 19:64-68, 1988.
104. Border WA, Okuda S, Nakamura T. Extracellular matrix and glomerular disease. Semin Nephrol 9(4):307-317, 1989.
105. Vleming LG, Baelde JJ, Westendorp RG, Daha MR, van Es LA, Bruijn JA. Progression of chronic renal disease in humans is associated with the deposition of basement membrane components and decorin in the interstitial extracellular matrix. Clin Nephrol 44:211-219, 1995.
106. Sharma AK, Mauer SM, Kim Y, Michael AF. Interstitial fibrosis in obstructive nephropathy. Kidney Int 44:774-788, 1993.
107. Merritt SE, Killen PD, Phan SH, Wiggins RC. Analysis of α1 (I) procollagen, α1 (IV) collagen, and β-actin mRNA in glomerulus and cortex of rabbits with experimental anti-glomerular basement membrane disease: evidence for early extraglomerular collagen biosynthesis. Lab Invest 63(6):762-769, 1990.